VentureMed Group Closes $28M Series C Led by S3 Ventures

Why It Matters

The infusion of $28 million gives VentureMed the resources to scale its innovative therapies in a rapidly expanding peripheral vascular market, strengthening its competitive position and paving the way for further strategic partnerships or follow‑on funding.

Deal Summary

VentureMed Group, a medical device company focused on vessel preparation and access management, closed a $28M Series C financing led by S3 Ventures with participation from existing investor Endeavour Vision. The round will support the company's development and commercialization efforts for treatments of peripheral arterial disease and vascular access.